Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: Involvement of CB1 receptors and TRPV1 channels

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 4026-4037

  Capasso, Raffaele ^a   Orlando, Pierangelo ^b   Pagano, Ester ^a   Aveta, Teresa ^c   Buono, Lorena ^c   Borrelli, Francesca ^a   Di Marzo, Vincenzo ^c   Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 5' IODORESINIFERATOXIN; ALLYL ISOTHIOCYANATE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GW 6471; MESSENGER RNA; N OLEOYLETHANOLAMINE; PALMIDROL; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ETHANOLAMINE DERIVATIVE; PALMITIC ACID DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; VANILLOID RECEPTOR; VEGETABLE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG INHIBITION; DRUG POTENTIATION; ENTERITIS; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; GENETICS; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAPERITONEAL DRUG ADMINISTRATION; IRRITABLE BOWEL SYNDROME; METABOLISM; MUSTARD;

ANIMALS; COLITIS; DISEASE MODELS, ANIMAL; ETHANOLAMINES; GASTROINTESTINAL MOTILITY; INFLAMMATION; INJECTIONS, INTRAPERITONEAL; IRRITABLE BOWEL SYNDROME; MALE; MICE; MICE, INBRED ICR; MUSTARD PLANT; PALMITIC ACIDS; PIPERIDINES; PLANT OILS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; TRPV CATION CHANNELS;

EID: 84905975128     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12759     Document Type: Article

References (67)

1. Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI, (2010). The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat. Neurogastroenterol Motil 22: 694, e206.
2. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S, (2008). Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 57: 923-929.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et-al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et-al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651
5. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M, (2013). Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 168: 1430-1444.
6. Aviello G, Matias I, Capasso R, Petrosino S, Borrelli F, Orlando P, et-al. (2008). Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med (Berl) 86: 413-422.
7. Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF, (2013). Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. CNS Neurol Disord Drug Targets 12: 23-33.
8. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V, (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.
9. Boesmans W, Owsianik G, Tack J, Voets T, Vanden Berghe P, (2011). TRP channels in neurogastroenterology: opportunities for therapeutic intervention. Br J Pharmacol 162: 18-37.
10. Borrelli F, Izzo AA, (2009). Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 23: 33-49.
11. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, et-al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 85: 1306-1316.
12. Calignano A, La Rana G, Makriyannis A, Lin SY, Beltramo M, Piomelli D, (1997). Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 340: R7-R8.
13. Calignano A, La Rana G, Giuffrida A, Piomelli D, (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
14. Camilleri M, (2012). Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 367: 1626-1635.
15. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, et-al. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134: 945-950.
16. Capasso R, Borrelli F, Cascio MG, Aviello G, Huben K, Zjawiony JK, et-al. (2008). Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 155: 681-689.
17. Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, et-al. (2013). Antiepileptic action of N-palmitoylethanolamine t hrough CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. Neuropharmacology 69: 115-126.
18. Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA, (2009). The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil 21: 420-429.
19. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, et-al. (2005). Involvement of the cannabimimetic compound, N-palmitoyl- ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154-1163.
20. D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, et-al. (2007). Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther 322: 1137-1143.
21. D'Argenio G, Petrosino S, Gianfrani C, Valenti M, Scaglione G, Grandone I, et-al. (2007). Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) 85: 523-530.
22. De Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, et-al. (2012). Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol 676: 41-50.
23. De Petrocellis L, Davis JB, Di Marzo V, (2001). Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506: 253-256.
24. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V, (2002). Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16: 297-302.
25. De Ponti F, (2013). Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol 4: 7.
26. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, et-al. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358: 249-255.
27. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, et-al. (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153: 1272-1280.
28. Di Paola R, Impellizzeri D, Torre A, Mazzon E, Cappellani A, Faggio C, et-al. (2012). Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. J Leukoc Biol 91: 911-920.
29. Diep TA, Madsen AN, Holst B, Kristiansen MM, Wellner N, Hansen SH, et-al. (2011). Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor. FASEB J 25: 765-774.
30. Esposito E, Cuzzocrea S, (2013). Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targets 12: 55-61.
31. Esposito E, Rinaldi B, Mazzon E, Donniacuo M, Impellizzeri D, Paterniti I, et-al. (2012). Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α. J Neuroinflammation 9: 81.
32. Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, et-al. (2014). Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut 63: 1300-1312.
33. Farquhar-Smith WP, Jaggar SI, Rice AS, (2002). Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97: 11-21.
34. Fichna J, Storr MA, (2012). Brain-gut interactions in IBS. Front Pharmacol 3: 127.
35. Fichna J, Wood JT, Papanastasiou M, Vadivel SK, Oprocha P, Salaga M, et-al. (2013). Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS ONE 8: e85073.
36. Forbes S, Herzog H, Cox HM, (2012). A role for neuropeptide Y in the gender-specific gastrointestinal, corticosterone and feeding responses to stress. Br J Pharmacol 166: 2307-2316.
37. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K, et-al. (2007). Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 282: 1518-1528.
38. Grimaldi P, Orlando P, Di Siena S, Lolicato F, Petrosino S, Bisogno T, et-al. (2009). The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106: 11131-11136.
39. Ho WS, Barrett DA, Randall MD, (2008). Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155: 837-846.
40. Holzer P, (2011). Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther 131: 142-170.
41. Izzo AA, (2013). Novel insights which may translate into treatments for irritable bowel syndrome. Front Pharmacol 4: 160.
42. Izzo AA, Coutts AA, (2005). Cannabinoids and the digestive tract. Handb Exp Pharmacol 168: 573-598.
43. Izzo AA, Capasso R, Pinto L, Di Carlo G, Mascolo N, Capasso F, (2001). Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 132: 1411-1416.
44. Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S, et-al. (2010). Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats. Obesity (Silver Spring) 18: 55-62.
45. Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, et-al. (2012). Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol 166: 1444-1460.
46. Kimball ES, Palmer JM, D'Andrea MR, Hornby PJ, Wade PR, (2005). Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice. Am J Physiol Gastrointest Liver Physiol 288: G1266-G1273.
47. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
48. Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ, (2010). Small intestinal cannabinoid receptor changes following a single colonic insult with oil of mustard in mice. Front Pharmacol 1: 132.
49. Laird JM, Martinez-Caro L, Garcia-Nicas E, Cervero F, (2001). A new model of visceral pain and referred hyperalgesia in the mouse. Pain 92: 335-342.
50. Lambert DM, Di Marzo V, (1999). The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6: 757-773.
51. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et-al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
52. Magge S, Lembo A, (2011). Complementary and alternative medicine for the irritable bowel syndrome. Gastroenterol Clin North Am 40: 245-253.
53. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
54. Okine BN, Rea K, Olango WM, Price J, Herdman S, Madasu MK, et-al. (2014). A role for PPAR-α in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats. Br J Pharmacol 171: 1462-1471.
55. O'Sullivan SE, Kendall DA, (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215: 611-616.
56. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et-al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Research 42 (Database Issue): D1098-1106
57. Petrosino S, Borrelli F, Pagano E, Di Marzo V, Izzo AA, (2013). Effect of palmitoylethanolamide in a murine model of colitis. XXXVI National Congress of the Italian Pharmacological Society; Turin (Italy).
58. Rahimi R, Abdollahi M, (2012). Herbal medicines for the management of irritable bowel syndrome: a comprehensive review. World J Gastroenterol 18: 589-600.
59. Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, et-al. (2013). The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol 169: 213-229.
60. Skaper SD, Facci L, Fusco M, Della Valle MF, Zusso M, Costa B, et-al. (2014). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology 22: 79-94.
61. Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ, (2002). 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136: 452-458.
62. Spiller R, (2004). Infection, immune function, and functional gut disorders. Clin Gastroenterol 2: 445-455.
63. Storr MA, Yüce B, Andrews CN, Sharkey KA, (2008). The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 20: 857-868.
64. Tsuboi K, Takezaki N, Ueda N, (2007). The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4: 1914-1925.
65. Voß U, Lewerenz A, Nieber K, (2012). Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol 214: 473-497.
66. Wade PR, Palmer JM, McKenney S, Kenigs V, Chevalier K, Moore BA, et-al. (2012). Modulation of gastrointestinal function by MuDelta, a mixed μ opioid receptor agonist/μ opioid receptor antagonist. Br J Pharmacol 67: 1111-1125.
67. Zhang SC, Wang WL, Su PJ, Jiang KL, Yuan ZW, (2014). Decreased enteric fatty acid amide hydrolase activity is associated with colonic inertia in slow transit constipation. J Gastroenterol Hepatol 29: 276-283.